Gary L. Mossman

Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in 1981 and is headquartered in East Rutherford, NJ.

PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX.

Glycos Biotechnologies, Inc. operates as a biochemical company which commercializes sustainable chemicals made from renewable feed stocks. It offers Lactic acid, Isoprene and Butadiene products. It also offers metabolic engineering and process development technology solutions. The company was founded by Ramon Y. Gonzalez and Syed Shams Yazdani in February 2007 and is headquartered in Houston, TX.

Dixie Chemical Co., Inc. manufactures and develops chemicals. The firm develops team-based solutions in the thermoset materials, alkaline paper sizing, and fuel and lube markets. The company was founded in 1946 and is headquartered in Pasadena, TX.

DX Oilfield Products LLC is a privately held company that offers oilfield products such as drilling fluid additives and oilfield chemicals. The company is based in Houston, TX. It is a subsidiary of Dixie Chemical.

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE.